PAVmed (PAVM) Fundamental Analysis: Revenue, Earnings & Valuation

9.99 / 10

Outperform

Fundamentally, PAVM scores 9.99/10, excelling in ROE, ROA, annualized equity return and net‑profit margin, all in top quartile. Cash‑MV and Profit‑MV are weak, dragging performance, but overall asset quality and profitability remain strong, supporting an Outperform rating.

Analysis Checks(7/10)

ROA (%)

Value0.84

Score3/3

Weight509.82%

1M Return1.79%

Annualized return on equity (%)

Value-17.25

Score3/3

Weight462.98%

1M Return1.64%

Profit-MV

Value0.08

Score1/3

Weight-1151.48%

1M Return-5.93%

Cash-UP

Value-0.01

Score2/3

Weight-834.25%

1M Return-3.92%

Annualized net profit margin on total assets (%)

Value1.12

Score3/3

Weight509.82%

1M Return1.79%

ROE (diluted) (%)

Value-5.97

Score3/3

Weight387.89%

1M Return1.39%

Asset-MV

Value-0.48

Score2/3

Weight977.64%

1M Return3.42%

ROE (%)

Value-12.94

Score3/3

Weight462.98%

1M Return1.64%

Cash-MV

Value-0.09

Score1/3

Weight-719.17%

1M Return-3.56%

Net profit / Total profit (%)

Value100.00

Score1/3

Weight-506.24%

1M Return-2.37%

Is PAVM undervalued or overvalued?

PAVM scores 9.99/10 on fundamentals and holds a Discounted valuation at present. Backed by its -20.71% ROE, -3477.46% net margin, -3.44 P/E ratio, 0.50 P/B ratio, and -105.68% earnings growth, these metrics solidify its Outperform investment rating.